


PRODUCT INFORMATION



Roquinimex

Item No. 30206

CAS Registry No.: 84088-42-6
Formal Name: 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
Synonyms: ABR 212616, FCF 89, Linomide, LS 2616, PNU 212616
MF: C₁₈H₁₆N₂O₃
FW: 308.3
Purity: ≥98%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Roquinimex is supplied as a solid. A stock solution may be made by dissolving the roquinimex in the solvent of choice, which should be purged with an inert gas. Roquinimex is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of roquinimex in ethanol and DMSO is approximately 3 mg/ml and approximately 5 mg/ml in DMF.

Roquinimex is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, roquinimex should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Roquinimex has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Roquinimex is an immunomodulator with diverse biological activities.¹⁻⁴ *In vivo*, roquinimex (80 mg/kg) increases the number of myocardial MHC class II-expressing cells, the ratio of cytotoxic to helper T cells, and survival and decreases necrotic lesion area in a mouse model of murine coxsackievirus B3-induced myocarditis.¹ It induces IFN-γ production, reduces TNF-α and IL-1β production, prevents the development of proteinuria, and ameliorates nephritis in a mouse model of chronic graft versus host disease (GVHD).² Roquinimex (300 mg/kg) decreases colonic myeloperoxidase (MPO) activity and mucosal damage in a mouse model of colitis induced by dextran sulfate (DSS; Item No. 23250).³ It also decreases tumor weight and tumor blood flow in a von Hippel-Lindau (VHL) type 2a paraganglioma mouse xenograft model.⁴

References

1. Ilbäck, N.G., Fohlman, J., Slorach, S., *et al. J. Immunol.* **142**(9), 3225-3228 (1989).
2. Xiao, Z.-Y., Zhou, W.-X., Zhang, Y.-X., *et al. Life Sci.* **81**(19-20), 1403-1410 (2007).
3. Liu, Q., Wang, Y., Wan, M.X., *et al. Inflamm. Res.* **52**(2), 64-68 (2003).
4. Gross, D.J., Reibstein, I., Weiss, L., *et al. Clin. Cancer Res.* **5**(11), 3669-3675 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM